Biogen Must Face Union Class Action Over Multiple Sclerosis Drug

A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera in employer health plans.

The decision is a reversal from Biogen’s previous victory in persuading the US District Court for the Northern District of Illinois to toss the case in June, after Judge April Perry ruled the plaintiff health plans did not plausibly allege that Biogen violated antitrust laws or prove they were directly injured by the alleged scheme.

The plaintiffs cured those deficiencies in their amended 10-count complaint, Perry ...